Physician profile
Dava C Hoffman
NPI 1760030084
$1,040.37
in general payments reported to CMS, 2019-2025
19 companies · $694 in 2025
The $694 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $59.65 · 2023: $31.74 · 2024: $124 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198.47 | 2024-2025 | |
| Amgen INC. | $174.44 | 2021-2025 | Repatha, Otezla, Tavneos |
| Novo Nordisk INC | $132.50 | 2025 | Ozempic, Rybelsus, Wegovy |
| Philips North America LLC | $76.01 | 2025 | Encore, Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $56.25 | 2022-2025 | Breztri |
| Novartis Pharmaceuticals Corporation | $46.78 | 2024-2025 | |
| Radius Health, INC. | $44.58 | 2022 | |
| Viatris Specialty LLC | $42.88 | 2025 | Yupelri |
| Exact Sciences Corporation | $36.92 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $34.40 | 2025 | Shingrix, Bexsero, Penmenvy |
| Bayer Healthcare Pharmaceuticals INC. | $32.22 | 2025 | |
| Merck Sharp & Dohme LLC | $29.15 | 2024-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Sumitomo Pharma America, INC. | $24.92 | 2025 | Gemtesa |
| Pacira Pharmaceuticals Incorporated | $22.03 | 2021 | |
| Verona Pharma, INC. | $20.03 | 2025 | Ohtuvayre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2025 | Jardiance |
| Lilly USA, LLC | $18.97 | 2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $17.75 | 2025 | Voquezna |
| Fidia Pharma USA INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dava Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.